{"id":"W2171889601","doi":"10.1016/s0140-6736(15)60125-8","title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":831,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Clinical trial; Blinding; Interleukin 17; Physical therapy; Dermatology; Psoriatic arthritis; Cytokine; Tumor necrosis factor alpha; Secukinumab; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1149020683539135,"score_gpt":0.3566539598176311,"score_spread":0.2417518914637176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}